Although immunohistochemistry for PD-L1 is utilized to identify a variety of cancers that are most likely to respond to anti-PD-1/PD-L1 therapy, including bladder cancer, breast cancer, non-small cell lung cancer, head and neck cancer, gastric cancer, esophageal and esophagogastric junction cancer, cervical cancer, and vulvar cancer, its predictive value for HCC response is questionable (8). This evidence concerns the gene CD274 and cancer.